WNT2B and hepatocellular carcinoma: This effect was blocked by the TLR9 agonist CpG ODN, which inhibited Wnt2b/β-catenin pathway activation and suppressed the M2 polarization of TAMs in hepatocellular carcinoma samples, ultimately reversing the tumour-promoting effects of the TAMs both in vitro and in vivo [159].